review thermo one knock
expect clearli increas come confer
back sever strong peer report dhr/pki/wat still manag
impress deliv anoth beat top bottom line report
organ revenu growth also beat alreadi elev expect
sens expect better given peer result
posit commentari healthcar confer acquisit ad
point growth fx tailwind segment perform
robust across board hsd organ growth lss sd lp
ai post second consecut dd quarter continu benefit
strong growth fei across industri scienc end market along
top-lin beat adjust ep also came consensu
look ahead compani provid initi guidanc revenu
ep rang street organ rang
expect assum typic initi guid increas
testament view tmo confid underli oper
environ overal much say hasnt alreadi said
fire cylind organ inorgan fei home
run pthn look solid despit hurrican headwind end market
continu look exceedingli healthi guidanc framework
set stage beat-and-rais year continu like set-up
reiter ow rate increas pt
revenu ep beat robust result across four segment
revenu organ came well consensus/jpm
report organ basi jpme sens
expect better given strong result
peer posit commentari healthcar confer driven
robust result across four segment segment organ basi ai
grew aid fei sd boost strong flu season lss
strong q/q improv lp bottom line adj ep
beat consensus/jpm driven top-lin beat off-set
slightli higher expect share count opm tax rate in-lin
estim in-lin margin impress given bp hit
took one-tim reform relat bonu payment employe
page analyst certif import disclosur
 morgan seek busi compani cover research report result investor awar
firm may conflict interest could affect object report investor consid report singl
factor make invest decis
guidanc come expect along strong quarterli result
also provid initi guidanc framework call
revenu ep rang street
organ rang expect start
year expect typic initi guid increas testament
view tmo confid underli oper environ includ
framework expect fx tailwind conserv given
recent declin usd boost acquisit bp opm
expans includ bp dilut pthn net interest expens
adjust tax rate bp reduct reform dilut
share count
maintain overweight increas pt overal
much say hasnt alreadi said simpli fire
cylind organ inorgan fei home run pthn
alreadi look solid despit hurrican headwind end market
continu look exceedingli healthi guidanc set stage
anoth beat-and-rais year continu like set-up reiter
overweight rate increas pt
lab product servic
 share count
invest thesi valuat risk
fire cylind organ inorgan fei home
run pthn look solid despit hurrican headwind end market
continu look exceedingli healthi guidanc framework set
stage beat-and-rais year continu like set-up
reiter ow rate increas decemb pt
price target price target deriv discount cash
flow analysi capm-deriv wacc discount rate termin
growth
risk rate price
downsid risk includ deterior global industri demand slow
pharma demand softer academ demand expect given increas
nih budget technolog shortfal includ inabl introduc
competit instrument consum time effect manner
lab product servi ce
good sold
pv termin val ue
perpetu growth ra te
equi ty va lue per sha
enterpris valu
thermo fisher scientif summari financi
cash equival
flow oper activ
o/w chang work capit
flow invest activ
sale
flow financ activ
net chang cash
adj free cash flow firm
compani report morgan estim
note million except per-shar data fiscal year end dec o/w
analyst certif research analyst denot ac cover report certifi multipl research
analyst primarili respons report research analyst denot ac cover within document
individu certifi respect secur issuer research analyst cover research view
express report accur reflect person view subject secur issuer part
research analyst compens directli indirectli relat specif recommend view
express research analyst report korea-bas research analyst list front cover also certifi per
kofia requir analysi made good faith view reflect opinion without undu influenc
